These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11705686)

  • 41. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
    Namba C; Tohyama M; Hanakawa Y; Murakami M; Shirakata Y; Matsumoto T; Suemori K; Ishii N; Hashimoto T; Sayama K
    J Dermatol; 2016 Apr; 43(4):419-22. PubMed ID: 26506947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis].
    Hellmich B
    Z Rheumatol; 2015 Mar; 74(2):157-8. PubMed ID: 25524229
    [No Abstract]   [Full Text] [Related]  

  • 43. [Immunosuppressive therapies for refractory nephrotic syndrome].
    Mitarai T
    Nihon Jinzo Gakkai Shi; 2010; 52(7):924-7. PubMed ID: 21077342
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunosuppression in the post-adaptation period.
    Halloran PF
    Transplantation; 2000 Jul; 70(1):3-5. PubMed ID: 10919566
    [No Abstract]   [Full Text] [Related]  

  • 45. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N; Patel NS; Cohen GF
    J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
    Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pemphigus vulgaris: an evidence-based treatment update.
    Zhao CY; Murrell DF
    Drugs; 2015 Feb; 75(3):271-84. PubMed ID: 25655250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bullous pemphigoid: diagnostics and new therapeutic strategies].
    Hofmann SC; Bruckner-Tuderman L
    Dtsch Med Wochenschr; 2006 Feb; 131(8):389-92. PubMed ID: 16479471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.
    Lever WF; Schaumburg-Lever G
    Arch Dermatol; 1977 Sep; 113(9):1236-41. PubMed ID: 900969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in the treatment of autoimmune bullous diseases.
    Takamori K
    J Dermatol; 2001 Nov; 28(11):654-7. PubMed ID: 11770728
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis.
    Atzmony L; Hodak E; Leshem YA; Rosenbaum O; Gdalevich M; Anhalt GJ; Mimouni D
    J Am Acad Dermatol; 2015 Aug; 73(2):264-71. PubMed ID: 26088689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.
    Busque S; Shoker A; Landsberg D; McAlister V; Halloran P; Shapiro J; Peets J; Schulz M
    Transplant Proc; 2001; 33(1-2):1266-7. PubMed ID: 11267285
    [No Abstract]   [Full Text] [Related]  

  • 53. Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice.
    Elmas ÖF; Demirbaş A; Türsen Ü; Atasoy M; Lotti T
    Dermatol Ther; 2020 Nov; 33(6):e14265. PubMed ID: 32882079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: Real-life evaluation.
    Alkeraye S; Becquart C; Delaporte E; Staumont-Sallé D
    J Dermatol; 2017 Dec; 44(12):e319-e320. PubMed ID: 28940756
    [No Abstract]   [Full Text] [Related]  

  • 55. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.
    Beissert S; Mimouni D; Kanwar AJ; Solomons N; Kalia V; Anhalt GJ
    J Invest Dermatol; 2010 Aug; 130(8):2041-8. PubMed ID: 20410913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Weekly cyclophosphamide pulse therapy combined with corticosteroids in the treatment of pemphigus].
    Jia GQ; Chen ZQ; Li HL; Cui PG; Xu WY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Apr; 23(2):173-5. PubMed ID: 12905897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
    Bigby M
    Arch Dermatol; 2004 Mar; 140(3):347-8. PubMed ID: 15023778
    [No Abstract]   [Full Text] [Related]  

  • 58. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil.
    Howell SM; Bessinger GT; Altman CE; Belnap CM
    J Am Acad Dermatol; 2005 Sep; 53(3):541-3. PubMed ID: 16112379
    [No Abstract]   [Full Text] [Related]  

  • 59. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study.
    Büsing M; Martin D; Schulz T; Heimes M; Klempnauer J; Kozuschek W
    Transplant Proc; 1998 Mar; 30(2):516-7. PubMed ID: 9532155
    [No Abstract]   [Full Text] [Related]  

  • 60. [Comparative evaluation of the treatment of pemphigus with corticosteroids and corticosteroids combined with immunosuppressive agents].
    Michałowski R; Kuczyńska L
    Przegl Dermatol; 1981; 68(2):227-32. PubMed ID: 7029660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.